The Czech Business Intuitive Handed OverNarrow moat

Synektik (SNT) — moat facet

Intuitive sold Synektik its own Czech business in 2022, and the installed base there has more than doubled since.

In most of Europe the direction of travel runs from distributor to manufacturer. Czechia and Slovakia ran the other way. The annex of 21 December 2021 extended Synektik's contract to both countries from 1 February 2022, and on that date Synektik's Czech subsidiary completed the purchase of two organised parts of the businesses of Intuitive Surgical Sàrl and Intuitive Surgical s.r.o. and began selling, servicing and training there1.

Czech and Slovak da Vinci systems under Synektik service16Sep 202224Sep 202330Sep 202438Sep 202542Jun 2026Synektik reports, 2022-2026, and press release of 17 September 2026
More than two and a half times the base Synektik took over.

Intuitive, in other words, preferred to have Synektik run a territory it had been running itself. Four years on the numbers justify the choice. The Czech and Slovak installed base under Synektik's care grew from 16 systems at September 2022, 13 in Czechia and 3 in Slovakia2, to 24 a year later3, 38 at September 20254 and 42 at June 20265. Procedures there went from 6,9 thousand in the year to September 2023 to 9,4 thousand and then 12,5 thousand in the year to September 20256.

The contract list shows the territory still buying. In the year to September 2025 the Czech subsidiary signed material contracts for da Vinci systems with the university hospitals in Olomouc, Plzeň and Bulovka in Prague, the Masaryk oncology institute in Brno, a private hospital group's site in Hořovice, and hospitals in Banská Bystrica and Bratislava in Slovakia, several with post-warranty service and consumables7. Czech and Slovak procedures rose 23% in the October-December 2025 quarter, to 3,4 thousand8, and 23% in the half-year to March 2026, to 7,4 thousand9.

Those robots are used hard. On the year-end installed base, Czech and Slovak systems performed roughly 330 procedures each in the year to September 2025, against about 264 in Poland10. A territory that a manufacturer handed over is also one where the distributor has to prove, every year, that it runs the business better than the manufacturer did.

Moat trajectory: Widening

Installed base up from 16 to 42 and procedures up by a third in the last year.

The number that tests this moat
Reported
Czech and Slovak da Vinci systems under Synektik service
42 at June 2026 (16 at September 2022)

The territory Intuitive handed over; its growth is Synektik's case for keeping it.

Source: Synektik press release on the first Estonian contract ↗
⚠ Threats to the moat
⚠ THREAT 01
Czech Growth Is Slowing
Synektik's Czech and Slovak robots are busier than Poland's, and their growth is half as fast.
References
  1. Reportedand began selling, servicing and training there.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  2. ReportedThe Czech and Slovak installed base under Synektik's care grew from 16 systems at September 2022, 13 in Czechia and 3 in Slovakia, to 24 a year later, 38 at September 2025 and 42 at June 2026.
    Synektik interim report for the fiscal year to 30 September 2022 - revenue, segments, installed base in Poland, Czechia and Slovakia, the first dedicated reimbursement and example tenders. — October 2021 - September 2022 · publ. November 2022 · source ↗
  3. ReportedThe Czech and Slovak installed base under Synektik's care grew from 16 systems at September 2022, 13 in Czechia and 3 in Slovakia, to 24 a year later, 38 at September 2025 and 42 at June 2026.
    Synektik quarterly report for the fourth quarter of the fiscal year to 30 September 2023 - revenue up 168%, order intake, recurring revenue, installed base and procedures. — October 2022 - September 2023 · publ. November 2023 · source ↗
  4. ReportedThe Czech and Slovak installed base under Synektik's care grew from 16 systems at September 2022, 13 in Czechia and 3 in Slovakia, to 24 a year later, 38 at September 2025 and 42 at June 2026.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  5. ReportedThe Czech and Slovak installed base under Synektik's care grew from 16 systems at September 2022, 13 in Czechia and 3 in Slovakia, to 24 a year later, 38 at September 2025 and 42 at June 2026.
    Synektik press release, 17 September 2026: 'Synektik signs first contract in Estonia. Another step in the Baltic states expansion' - EUR 9,4 million including nine years of maintenance and ten years of consumables; 142 systems (100 in Poland, 42 in Czechia and Slovakia); the Ukraine plan; targets for foreign and recurring revenue. — September 2026 · publ. 17 September 2026 · source ↗
  6. ReportedProcedures there went from 6,9 thousand in the year to September 2023 to 9,4 thousand and then 12,5 thousand in the year to September 2025.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  7. ReportedIn the year to September 2025 the Czech subsidiary signed material contracts for da Vinci systems with the university hospitals in Olomouc, Plzeň and Bulovka in Prague, the Masaryk oncology institute in Brno, a private hospital group's site in Hořovice, and hospitals in Banská Bystrica and Bratislava in Slovakia, several with post-warranty service and consumables.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  8. ReportedCzech and Slovak procedures rose 23% in the October-December 2025 quarter, to 3,4 thousand, and 23% in the half-year to March 2026, to 7,4 thousand.
    Synektik interim financial statements for 1 October - 31 December 2025 - including the annex extending the da Vinci distribution agreement to 31 December 2031 and adding Ukraine, and the 10,75 złoty dividend. — October - December 2025 · publ. February 2026 · source ↗
  9. ReportedCzech and Slovak procedures rose 23% in the October-December 2025 quarter, to 3,4 thousand, and 23% in the half-year to March 2026, to 7,4 thousand.
    Synektik management board report for the half-year 1 October 2025 - 31 March 2026 - including the HistoSonics Edison exclusive distribution agreement and the installed base at March 2026. — October 2025 - March 2026 · publ. June 2026 · source ↗
  10. Moat Explorer calcOn the year-end installed base, Czech and Slovak systems performed roughly 330 procedures each in the year to September 2025, against about 264 in Poland.
    Moat Explorer calculation from Synektik's reported figures (thousands of złoty unless stated). Market value: 352,60 złoty x 8 529 129 shares = 3 007,4 million złoty (about 3,0 billion złoty); at the NBP rate of 3,8570 = $779,7 million (about $780 million). Trailing revenue to June 2026: 681 598,6 - 482 060,1 + 733 427,1 = 932 965,6 (about 933 million złoty). Trailing continuing net profit: 126 019,2 - 85 705,2 + 137 952,7 = 178 266,7; over 8 529 129 shares = 20,90 złoty; P/E 352,60 / 20,90 = 16,9. Equipment and IT segment EBITDA over segment revenue: 187 190,7 / 631 915,5 = 29,6% (FY2025); 143 577,5 / 579 299,1 = 24,8% (FY2024); 98 943,8 / 410 834,1 = 24,1% (FY2023); 29 865,3 / 139 272,7 = 21,4% (FY2022); 18 636,4 / 100 878,6 = 18,5% (FY2021); 19 605,9 / 112 126,1 = 17,5% (FY2019). Radiopharmaceutical segment EBITDA margin: 16 061,3 / 52 937,4 = 30,3% (FY2025); 16 276,6 / 46 615,7 = 34,9% (FY2024). Recurring revenue, trailing: 374,7 / 59,8 = 6,3 times (September 2022 to June 2026); installed base 142 / 37 = 3,8 times. Recurring revenue per year-end robot: 311,3 / 113 = 2,75 million złoty (FY2025); 193,9 / 86 = 2,25 million złoty (FY2024). Procedures per year-end robot, FY2025: Poland 19 800 / 75 = 264; Czechia and Slovakia 12 500 / 38 = 329. Revenue per average employee: 681,6 / 221 = 3,08 million złoty. Export share: 183,7 / 681,6 = 27,0%. Equipment segment share of revenue excluding intragroup sales: 631,1 / 681,6 = 92,6% (about 93%). Intuitive products: 44,9% x 681,6 = 306,0 million złoty; other equipment, IT and service 681,6 - 306,0 - 50,5 = 325,1 million złoty. Synektik market value over the Estonian contract: 3 007,4 / 41 = 73 (roughly seventy). Dividend paid February 2026: 10,75 x 8 529 129 = 91,7 million złoty; dividend per share 10,75 / 0,45 = 23,9 times since 2021. Free cash flow: FY2025 78,3 - 17,4 = 60,9 million złoty; FY2024 89,6 - 44,9 = 44,7 million złoty. IT4KAN price over market value: 4,15 / 3 007,4 = 0,14%. Recurring revenue, April-June 2025: 103,6 / 1,26 = 82,2 million złoty. Backlog plus active offers at June 2026: 44,2 + 160,8 = 205,0 million złoty. NFZ spending per robotic operation: 59 / 2,1 = 28 thousand złoty (2022); 167 / 5,4 = 31 thousand złoty (2023); 300 / 11 = 27 thousand złoty (2024). NFZ-funded PET studies: 96,1 / 89,3 - 1 = 7,6% (about 8%); per scanner 96 100 / 37 = about 2 600. Affidea: 29,0% x 52,9 = 15,3 million złoty, against segment EBITDA of 16,1 million złoty. Synektik's installed base as a share of Intuitive's: 142 / 11 710 = 1,2%. Czech and Slovak installed base: 42 / 16 = 2,6 times. Equipment segment purchases from others: 100 - 80,2 - 6,8 = 13,0%. Years of exclusivity from September 2026 to 31 December 2031: about 5,3. Year-end P/E and P/S (market value at 30 September over net profit and revenue; continuing profit from FY2024): 122,8 / 9,136 = 13,4 and 122,8 / 134,8 = 0,91 (FY2019); 190,2 / 8,811 = 21,6 and 1,52 (FY2020); 252,5 / 8,384 = 30,1 and 1,96 (FY2021); 237,5 / 10,709 = 22,2 and 1,42 (FY2022); 516,9 / 52,452 = 9,9 and 1,16 (FY2023); 1 635,9 / 98,909 = 16,5 and 2,62 (FY2024); 2 149,3 / 126,019 = 17,1 and 3,15 (FY2025); market values from closing prices of 14,40 złoty, 22,30, 29,60, 27,85, 60,60, 191,80 and 252,00 x 8 529 129. — October 2018 - June 2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in Synektik's financial statements, management board reports, factsheet and market data; operands shown in the source line.
Sources
Generated September 24, 2026